

Special Issue on
**Atherothrombosis: An Update on Current Management
and Theranostics**

CALL FOR PAPERS

Atherothrombosis is a complex disease, a major health care burden, and the leading cause of mortality throughout the world. The decrease in blood supply due to the narrowed vasculature and rupture of atherosclerotic plaques adds to this by thrombus formation mediated by the activation of the coagulation cascade. Associated complications include myocardial infarction, congestive heart failure, coronary artery disease, systemic hypertension, arrhythmia, and sudden cardiac death. Atherosclerotic plaques contain highly thrombogenic proteins, including the platelet activator collagen and the procoagulant tissue factor. Plaque rupture in an atherosclerotic artery leads to denudation of the arterial surface and exposure of the procoagulant to blood flow, resulting in the formation of a thrombus and emboli.

Vascular intervention to treat atherosclerotic arteries causes injury to the endothelial surface of the artery and results in arterial inflammation and results in thrombus formation. Thus far, antiplatelet therapy has been used as secondary prevention in these patients. However, at present, a combination of antiplatelet and anticoagulant therapy is gaining interest specifically with regard to therapeutic strategies that aim to decrease atherothrombotic events by optimization of vascular protection. Preventing plaque formation and its rupture and thrombotic events along with revascularization are the main challenges. However, the current drug therapies of using antiplatelet drugs, anticoagulants, and drugs targeting factors VII and X to prevent ischemic events are associated with increased bleeding episodes. Thus, there is a need to improve treatment strategies addressing these existing challenges.

This special issue welcomes the submission of original research and review articles focusing on the use of novel drugs as well as drug combinations for antiplatelet therapy, comparison of triple antiplatelet therapy, and targeting factors in coagulation cascade such as Thromboxane A Synthase, as well as using tissue plasminogen inhibitors and rivaroxaban. Articles discussing and critically evaluating ongoing clinical trials including APPRAISE and ATLAS ACS TIMI, ATHENA, CIRT, TROIA-ACS, COMPASS, and CHARISMA are of particular interest.

Potential topics include but are not limited to the following:

- ▶ Atherosclerosis and atherothrombosis
- ▶ Complications associated with atherothrombosis
- ▶ Antiplatelet therapy and targeting coagulation cascade in atherothrombosis
- ▶ Current treatment strategies and treating cardiovascular complications
- ▶ Ongoing recent clinical trials results with clopidogrel in prevention of atherothrombosis

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/crp/athero/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Vikrant Rai, Creighton University
School of Medicine, Omaha, USA
vikrantrai@creighton.edu

Guest Editors

Devendra K. Agrawal, The Peekie Nash
Carpenter Endowed Chair in Medicine,
Omaha, USA
dkagr@creighton.edu

Jason Patregnani, Cardiac Critical Care,
Washington, District of Columbia, USA
jpatregnani@gmail.com

Submission Deadline

Friday, 8 February 2019

Publication Date

June 2019